Alzheimer case-control samples originate from the EU funded AddNeuroMed Cohort, which is a large cross-European AD biomarker study relying on human blood as the source of DNA.
Overall design
Case-control design. Cases are Alzheimer's disease patients, individuals with mild cognitive impairment (MCI), or controls. The individuals with MCI can be further divided into individuals who had MCI at baseline blood extraction but progressed to AD within one year, or MCI individuals who didn't progress to AD within one year (see characteristics: disease status2). The criterion 'age<65.exclusion' indicates whether samples were taken into account after applying the exclusion criterion of individuals who are younger than 65 years of age.
Less...
More...